SCHEMBL688500

SCHEMBL688500

O=S(=O)(Cc1cc[c]cc1)c1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.61
TSHR P16473 2/20 0.53
HSD17B10 Q99714 1/20 0.53
PSIP1 O75475 1/20 0.48
FAAH O00519 1/20 0.42
PRSS1 P07477 1/20 0.42
PRSS2 P07478 1/20 0.42
ELANE P08246 1/20 0.42
PRTN3 P24158 1/20 0.42
PRSS3 P35030 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA5A P35218 1/20 0.42
CA9 Q16790 1/20 0.42
DAO P14920 1/20 0.41
SMN1; SMN2 Q16637 4/20 0.41
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
LTA4H P09960 1/20 0.40
HTR6 P50406 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL865097 0.92 TSHR (0.58) MAPTTSHRHSD17B10PSIP1FAAH
Benzylsulfonylbenzene SCHEMBL780337 0.85 TSHR (0.68) MAPTTSHRHSD17B10PSIP1FAAH
Benzylsulfonylbenzene SCHEMBL1877584 0.83 TSHR (0.66) MAPTTSHRHSD17B10PSIP1FAAH
SCHEMBL21194959 0.81 GAA (0.50) MAPTTSHRHSD17B10PSIP1CA1
SCHEMBL28111261 0.81 MLNR (0.43) MAPTTSHRHSD17B10PSIP1CA1
SCHEMBL3097873 0.81 PSEN1 (0.46) MAPTTSHRHSD17B10CA1CA2
SCHEMBL4614031 0.79 CA2 (0.50) TSHRHSD17B10FAAHPRSS1PRSS2
SCHEMBL11114440 0.76 MAPT (0.61) MAPTTSHRHSD17B10PSIP1CA2
SCHEMBL22511307 0.76 MAPT (0.61) MAPTTSHRHSD17B10PSIP1FAAH
SCHEMBL9820015 0.76 MAPT (0.61) MAPTTSHRHSD17B10PSIP1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024146922-A1 C5AR1 INHIBITORS FOR USE IN THE TREATMENT OF OCULAR MUCOUS MEMBRANE PEMPHIGOID AND/OR ORAL MUCOUS MEMBRANE PEMPHIGOID DOMPE' FARMACEUTICI SPA (IT) 2024-07-11 WO claimed
EP-4397306-A1 C5AR1 INHIBITORS FOR USE IN THE TREATMENT OF OCULAR MUCOUS MEMBRANE PEMPHIGOID AND/OR ORAL MUCOUS MEMBRANE PEMPHIGOID Dompe' Farmaceutici S.P.A. (IT) 2024-07-10 EP claimed
US-20240180888-A1 C5AR1 INHIBITORS FOR TREATING HYPERSENSITIVITY REACTIONS TO TAXANES DOMPE' FARMACEUTICI SPA (IT) 2024-06-06 US claimed
EP-4308114-A1 C5AR1 INHIBITORS FOR TREATING HYPERSENSITIVITY REACTIONS TO TAXANES Dompe' Farmaceutici SpA (IT) 2024-01-24 EP claimed
CN-117337176-A C5AR1 inhibitors for treating hypersensitivity to taxanes 东佩制药股份公司 2024-01-02 CN claimed
US-20200397725-A1 C5AR INHIBITORS FOR USE IN THE TREATMENT OF CHEMOTHERAPY-INDUCED IATROGENIC PAIN DOMPE' FARMACEUTICI S.P.A. (IT) 2020-12-24 US claimed
EP-3723744-A2 C5AR INHIBITORS FOR USE IN THE TREATMENT OF CHEMOTHERAPY-INDUCED IATROGENIC PAIN Dompé farmaceutici S.p.A. (IT) 2020-10-21 EP claimed
CN-111511363-A C5aR inhibitors for the treatment of chemotherapy-induced iatrogenic pain 多姆皮制药公司 2020-08-07 CN claimed
WO-2019115493-A2 C5AR INHIBITORS FOR USE IN THE TREATMENT OF CHEMOTHERAPY-INDUCED IATROGENIC PAIN DOMPE' FARMACEUTICI S.P.A. (IT) 2019-06-20 WO claimed
EP-3498269-A1 C5AR INHIBITORS FOR USE IN THE TREATMENT OF CHEMOTHERAPY-INDUCED IATROGENIC PAIN Dompé farmaceutici S.p.A. (IT) 2019-06-19 EP claimed
WO-2007060215-A2 (R)-ARYLKYLAMINO DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DOMPE' PHA.R.MA S.P.A. (IT) 2007-05-31 WO claimed
US-20060258730-A1 Sulfonic acids, their derivatives and pharmaceutical compositions containing them DOMPE S.P.A. (IT) 2006-11-16 US claimed
EP-1663960-A2 AMIDINES AND DERIVATIVES THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DOMPE' pha.r.ma s.p.a. (IT) 2006-06-07 EP claimed
EP-1606248-A2 SULFONIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Dompé S.P.A. (IT) 2005-12-21 EP claimed
WO-2005028425-A2 AMIDINES AND DERIVATIVES THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DOMPÉ PHA.R.MA S.P.A. (IT) 2005-03-31 WO claimed
US-20050038119-A1 2-Aryl-propionic acids and pharmaceutical compositions containing them DOMPÉ FARMACEUTICI S.P.A. (IT) 2005-02-17 US claimed
WO-2004080951-A2 SULFONIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DOMPE S.P.A. (IT) 2004-09-23 WO claimed
EP-1455773-A1 2-ARYL-PROPIONIC ACIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Dompé S.P.A. (IT) 2004-09-15 EP claimed
EP-1457485-A1 Sulfonic acids, their derivatives and pharmaceutical compositions containing them Dompé S.P.A. (IT) 2004-09-15 EP claimed
WO-2003043625-A1 2-ARYL-PROPIONIC ACIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DOMPE S.P.A. (IT) 2003-05-30 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240180888-A1 C5AR1 INHIBITORS FOR TREATING HYPERSENSITIVITY REACTIONS TO TAXANES C5AR1, C5AR2, C3AR1 MAPT 3127/4885TSHR 791/4885HSD17B10 2904/4885
US-20200397725-A1 C5AR INHIBITORS FOR USE IN THE TREATMENT OF CHEMOTHERAPY-INDUCED IATROGENIC PAIN C5AR2, C5AR1, C3AR1 MAPT 4697/4885TSHR 829/4885HSD17B10 4705/4885
US-20060258730-A1 Sulfonic acids, their derivatives and pharmaceutical compositions containing them CCR8, CCR1, CXCR1 MAPT 4777/4885TSHR 2534/4885HSD17B10 4428/4885
US-20050038119-A1 2-Aryl-propionic acids and pharmaceutical compositions containing them CXCR2, FPR1, CCR2 MAPT 4538/4885TSHR 1315/4885HSD17B10 3357/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.